Literature DB >> 8595919

Pulmonary immunity to Pseudomonas aeruginosa.

A W Cripps1, M L Dunkley, R L Clancy, J Kyd.   

Abstract

Pseudomonas aeruginosa, an opportunistic bacterial pathogen, is a major course of morbidity and mortality in subjects with compromised respiratory function despite the significant advances in therapeutic practices. The bacteria produces an armoury of products which modify its infective niche to ensure bacterial survival. The role of antibody in protection against pulmonary infection remains poorly defined. Protection appears to be associated with opsonizing antibody whilst some other antibody responses may be deleterious and promote further lung damage. Cell mediated responses are clearly important in protection against infection. This review proposes a vaccine strategy aimed at enhancing specific T cell responses in the lung which, though T cell-derived cytokines, drive the recruitment of neutrophils to the lung and the subsequent activation of these cells results in the clearance of bacteria from the lung.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8595919     DOI: 10.1038/icb.1995.65

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  14 in total

1.  Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells.

Authors:  S Worgall; T Kikuchi; R Singh; K Martushova; L Lande; R G Crystal
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.

Authors:  Rika Gomi; Anurag Sharma; Wenzhu Wu; Biin Sung; Stefan Worgall
Journal:  Vaccine       Date:  2017-11-07       Impact factor: 3.641

3.  Identification of Pseudomonas aeruginosa-induced genes in human mast cells using suppression subtractive hybridization: up-regulation of IL-8 and CCL4 production.

Authors:  Genlou Sun; Fang Liu; Tong-Jun Lin
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

4.  Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

Authors:  Stefan Worgall; Anja Krause; Michael Rivara; Kyung-Kim Hee; Enrico V Vintayen; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

5.  Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.

Authors:  Antonio DiGiandomenico; Jayasimha Rao; Joanna B Goldberg
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

6.  The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity.

Authors:  G Telford; D Wheeler; P Williams; P T Tomkins; P Appleby; H Sewell; G S Stewart; B W Bycroft; D I Pritchard
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

7.  Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa.

Authors:  C Morissette; C Francoeur; C Darmond-Zwaig; F Gervais
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa.

Authors:  S Jain-Vora; A M LeVine; Z Chroneos; G F Ross; W M Hull; J A Whitsett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa.

Authors:  Tong-Jun Lin; Lauren H Maher; Kaede Gomi; Jeffrey D McCurdy; Rafael Garduno; Jean S Marshall
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  Autophagy enhances bacterial clearance during P. aeruginosa lung infection.

Authors:  Robert D Junkins; Ann Shen; Kirill Rosen; Craig McCormick; Tong-Jun Lin
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.